American Asset Management Trimmed General Electric Co (GE) Position By $323,884; Last Week BioScrip, Inc. (BIOS) Coverage

May 21, 2018 - By Henry Gaston

General Electric Company (NYSE:GE) Logo

Among 6 analysts covering BioScrip (NASDAQ:BIOS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, January 3 by Lake Street. On Wednesday, December 20 the stock rating was maintained by SunTrust with “Buy”. Dougherty & Company maintained BioScrip, Inc. (NASDAQ:BIOS) on Wednesday, August 12 with “Buy” rating. The rating was maintained by SunTrust on Thursday, November 2 with “Buy”. The stock has “Buy” rating by SunTrust on Thursday, August 10. The stock of BioScrip, Inc. (NASDAQ:BIOS) earned “Buy” rating by Jefferies on Thursday, June 8. As per Wednesday, August 9, the company rating was maintained by Jefferies. As per Thursday, November 2, the company rating was maintained by Jefferies. The stock of BioScrip, Inc. (NASDAQ:BIOS) has “Buy” rating given on Wednesday, April 11 by Barrington. As per Thursday, March 8, the company rating was maintained by SunTrust. See BioScrip, Inc. (NASDAQ:BIOS) latest ratings:

11/04/2018 Broker: Barrington Rating: Buy New Target: $3.5000 Maintain
08/03/2018 Broker: SunTrust Rating: Buy New Target: $3.25 Maintain
20/12/2017 Broker: SunTrust Rating: Buy New Target: $3.5 Maintain

American Asset Management Inc decreased General Electric Co (GE) stake by 54.22% reported in 2017Q4 SEC filing. American Asset Management Inc sold 19,052 shares as General Electric Co (GE)’s stock declined 23.20%. The American Asset Management Inc holds 16,087 shares with $281,000 value, down from 35,139 last quarter. General Electric Co now has $130.02 billion valuation. The stock decreased 0.40% or $0.06 during the last trading session, reaching $14.97. About 34.36M shares traded. General Electric Company (NYSE:GE) has declined 54.35% since May 21, 2017 and is downtrending. It has underperformed by 65.90% the S&P500.

Investors sentiment decreased to 0.5 in 2017 Q4. Its down 0.19, from 0.69 in 2017Q3. It dived, as 153 investors sold GE shares while 921 reduced holdings. 151 funds opened positions while 383 raised stakes. 4.69 billion shares or 0.29% less from 4.70 billion shares in 2017Q3 were reported. The Alabama-based Notis has invested 0.85% in General Electric Company (NYSE:GE). 256,408 are held by Edgar Lomax Va. The Ohio-based Strs Ohio has invested 0.48% in General Electric Company (NYSE:GE). Westwood Management Corp Il holds 0.03% or 10,500 shares in its portfolio. Fairfield Bush & invested 0.29% of its portfolio in General Electric Company (NYSE:GE). Millennium Mgmt Limited Liability, a New York-based fund reported 2.57M shares. Mai Mngmt owns 309,154 shares for 0.31% of their portfolio. Whitnell And Co owns 0.3% invested in General Electric Company (NYSE:GE) for 40,994 shares. 42.35 million were accumulated by Price T Rowe Md. Timber Creek Cap Limited Liability Com, a Massachusetts-based fund reported 95,750 shares. Tctc Limited Liability Company accumulated 659,965 shares or 0.6% of the stock. 405,102 are held by Chesley Taft Associates Lc. Boston Private Wealth Ltd stated it has 787,626 shares or 0.52% of all its holdings. Leavell Management accumulated 51,054 shares. Lafayette Incorporated has invested 0.1% in General Electric Company (NYSE:GE).

More notable recent General Electric Company (NYSE:GE) news were published by: which released: “Wabtec and GE Transportation to merge” on May 21, 2018, also with their article: “General Electric: Selling Low?” published on May 17, 2018, published: “GE nears $20 billion deal to sell transportation unit to Wabtec: report” on May 21, 2018. More interesting news about General Electric Company (NYSE:GE) were released by: and their article: “General Electric’s Death Could Be Best For Shareholders” published on April 25, 2018 as well as‘s news article titled: “General Electric: Finally, It’s Over” with publication date: April 23, 2018.

Since January 26, 2018, it had 1 buying transaction, and 0 insider sales for $43,446 activity. 2,689 shares were bought by DIMITRIEF ALEXANDER, worth $43,446 on Friday, January 26.

Analysts await General Electric Company (NYSE:GE) to report earnings on July, 20. They expect $0.18 earnings per share, down 35.71% or $0.10 from last year’s $0.28 per share. GE’s profit will be $1.56 billion for 20.79 P/E if the $0.18 EPS becomes a reality. After $0.16 actual earnings per share reported by General Electric Company for the previous quarter, Wall Street now forecasts 12.50% EPS growth.

Among 29 analysts covering General Electric Company (NYSE:GE), 9 have Buy rating, 6 Sell and 14 Hold. Therefore 31% are positive. General Electric Company had 102 analyst reports since July 21, 2015 according to SRatingsIntel. On Tuesday, October 20 the stock rating was maintained by S&P Research with “Buy”. On Monday, November 13 the stock rating was upgraded by Langenberg to “Buy”. The stock of General Electric Company (NYSE:GE) earned “Hold” rating by Oppenheimer on Monday, June 12. The firm earned “Sell” rating on Friday, July 22 by Standpoint Research. The firm has “Hold” rating given on Friday, January 26 by DZ Bank. The firm has “Buy” rating by Bank of America given on Tuesday, November 14. RBC Capital Markets maintained the stock with “Hold” rating in Monday, April 23 report. The stock of General Electric Company (NYSE:GE) earned “Sell” rating by Deutsche Bank on Monday, October 30. Credit Suisse upgraded General Electric Company (NYSE:GE) on Wednesday, September 16 to “Focus List” rating. The company was maintained on Monday, April 24 by RBC Capital Markets.

The stock decreased 0.80% or $0.02 during the last trading session, reaching $2.48. About 508,219 shares traded. BioScrip, Inc. (NASDAQ:BIOS) has risen 42.70% since May 21, 2017 and is uptrending. It has outperformed by 31.15% the S&P500.

Investors sentiment increased to 1.18 in Q4 2017. Its up 0.13, from 1.05 in 2017Q3. It improved, as 12 investors sold BioScrip, Inc. shares while 28 reduced holdings. 19 funds opened positions while 28 raised stakes. 104.07 million shares or 0.29% less from 104.38 million shares in 2017Q3 were reported. Gamco Invsts Et Al invested 0.01% in BioScrip, Inc. (NASDAQ:BIOS). Tower Cap Lc (Trc) holds 0% in BioScrip, Inc. (NASDAQ:BIOS) or 8,724 shares. Thompson Siegel Walmsley Lc reported 1,900 shares. Janney Montgomery Scott Llc owns 0% invested in BioScrip, Inc. (NASDAQ:BIOS) for 15,528 shares. Salzhauer Michael stated it has 24,075 shares or 0.03% of all its holdings. Credit Suisse Ag holds 42,571 shares. The Massachusetts-based Portolan Capital Management Ltd has invested 0.12% in BioScrip, Inc. (NASDAQ:BIOS). Ares Lc accumulated 0.59% or 6.36M shares. 92,855 are owned by Manufacturers Life The. Parallax Volatility Advisers Lp holds 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS) for 16,170 shares. Vanguard Group Inc holds 0% or 5.40M shares in its portfolio. D E Shaw And reported 0.02% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). Royal Commercial Bank Of Canada reported 115,232 shares. Jpmorgan Chase And reported 61,462 shares. New York State Common Retirement Fund has 0% invested in BioScrip, Inc. (NASDAQ:BIOS) for 116,700 shares.

More recent BioScrip, Inc. (NASDAQ:BIOS) news were published by: which released: “BioScrip to Participate in Upcoming Investor Conferences” on May 16, 2018. Also published the news titled: “BioScrip Reports First Quarter 2018 Financial Results” on May 10, 2018.‘s news article titled: “BioScrip (BIOS) Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018 was also an interesting one.

BioScrip, Inc. provides home infusion services in the United States. The company has market cap of $317.32 million. The firm engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It currently has negative earnings. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

General Electric Company (NYSE:GE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.